MNOV — MEDICINOVA INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1226616 ·
Last close
$1.34
Market Cap
$68.65M
52W High
$3.90
52W Low
$1.22
ADV30
61,093
Next earnings
2026-11-12
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 138,555 55,849 -3,060,224 -2,842,962 45,242,293 29,256,294 4,147,795
Jun 2026 458,439 317,759 -2,541,189 -2,314,139 40,433,469 25,415,921 3,162,867
Mar 2026 186,984 16,883 -2,835,806 -2,586,258 42,704,854 27,329,415 3,297,620
Dec 2025 151,739 4,754 -3,092,402 -2,802,279 45,603,109 30,806,477 4,016,428

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-9,110,256
Investing CF
$-13,724
Financing CF
—
CapEx
$-10,825
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-443,649,596
Inventory
—
Receivables
$245,100
ST Investments
—
EBIT TTM
$-11,850,395
Pretax Income TTM
$-10,747,055
Interest Exp TTM
—
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$935,717
EBITDA
$-11,512,367
Free Cash Flow
$-6,790,181
Enterprise Value
$42,313,812
Total Cash
$29,256,294
Total Debt
$100,536
Shares Out
51,232,668
Trailing EPS
$-0.21
Book Value
$0.76
ROE
-24.8%
ROA
-15.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 409,657 -13,283,002 -11,997,957 45,603,109 4,016,428 41,586,681 -9,810,061
Dec 2024 0 -12,675,331 -11,049,549 55,875,926 3,372,375 52,503,551 -10,642,964
Dec 2023 1,000,000 -9,900,265 -8,571,516 66,269,977 3,891,553 62,378,424 -7,431,038
Dec 2022 0 -14,628,649 -14,069,083 74,154,905 3,912,870 70,242,035 -12,911,563

TTM Snapshot

Revenues TTM
$920,481
NetIncome TTM
$-10,753,049
OpCashFlow TTM
—
Assets (Latest)
$40,433,469
Forward EPS
$-0.52

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.33 · call volume: 1 · put volume: 1
Expected Move to 2027-01-15: ±$1.38 (103.38%) — implied range $-0.04 – $2.71 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CING Cingulate Inc. $68.64M $4.72 —
VTVT vTv Therapeutics Inc. $69.36M $17.29 —
GOSS Gossamer Bio, Inc. $67.52M $11.04 —
COYA Coya Therapeutics, Inc. $70.84M $3.02 —
KALA KALA BIO, Inc. $66.34M $3.43 —

News headlines (Yahoo Finance, 1h cache)

MediciNova (MNOV) Reports Q3 Loss, Misses Revenue Estimates
2026-11-12 23:35 · Yahoo
MediciNova: Q3 Earnings Snapshot
2026-11-12 22:32 · Yahoo
MediciNova CEO Provides Shareholder Update
2026-10-12 10:00 · Yahoo
MediciNova to Participate in the Maxim Growth Summit
2026-10-06 10:00 · Yahoo
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
2026-09-28 15:10 · Yahoo
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
2026-09-28 13:58 · Yahoo
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
2026-09-28 13:20 · Yahoo
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
2026-09-28 10:00 · Yahoo
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
2026-09-24 10:00 · Yahoo
MediciNova to Participate in Two Investor Conferences in September
2026-09-08 10:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.